Doctors were Wrong about Cholesterol and Heart Disease

Physionic

Dec 29, 2025

Episode description

JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]
Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2

HEALTH AUTONOMY [COURSE]
Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy

JOIN THE COMMUNITY
Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2

EMAIL LIST
1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6

HIRE ME FOR CONSULTING:
Consulting: https://bit.ly/3dmUl2H

Created with Biorender

Blood Pressure and Heart Disease: https://youtu.be/34cMamNp2Uo?si=uvV2yw0hcrLUDQZG

0:00 - Introduction
1:00 - Why Doctors were Wrong
1:49 - The First Wave of Evidence
3:55 - The Second Wave of Evidence
5:42 - HDL and Mortality, HDL Dysfunction
8:54 - How I'd Approach this

References
*Funding/Conflicts of Interest did not fit in the Description (there is a character limit); however, you can access both by joining my free email list or free Physionic Community

[1] Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707-714. doi:10.1016/0002-9343(77)90874-9

[Study 562] AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267. doi:10.1056/NEJMoa1107579

[Study 563] HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-212. doi:10.1056/NEJMoa1300955

[Study 564] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-2122. doi:10.1056/NEJMoa0706628

[Study 565] Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089-2099.

[Study 566] Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580. doi:10.1016/S0140-6736(12)60312-2

[Study 567] Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539-550. doi:10.1093/eurheartj/eht57

[Study 568] von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J. 2023;44(16):1394-1407. doi:10.1093/eurheartj/ehac605

CRITIQUES, RULES, AND NOTES

Be aware of the following rules before posting comments:
- Please do not post summaries of the video in the comments - it damages retention on the video and YouTube is less likely to promote it (these videos cost me a lot of money to produce).

Critiques of my work are welcome! Please be aware of the following notes & rules before submitting critique:

Be mindful that this content is not all encompassing on the subject at hand and is self-limited for brevity to reach a wider audience. Also, be aware that I receive hundreds of YouTube comments per day, so the only way your critique can be considered is if you follow the steps outlined below. Finally, YouTube auto-deletes links, so I do not see most comments with links attached.

RULES:
If your comment is rude, you will be banned.
If your comment is not about the studies/topics at hand (i.e. extending to other outcomes not discussed) or offers critique with no scientific basis, it is unlikely to receive a response.

If you can follow these rules, I will try to address your critique and if there is merit, I will add an AMENDMENT to the content in question and pin it so everyone can see it (thank you!).

Please use the following link to submit your critique: https://bit.ly/PhysionicCritique

Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.

#hearthealth #heartdiseaseprevention

Episode description

JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]
Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2

HEALTH AUTONOMY [COURSE]
Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy

JOIN THE COMMUNITY
Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2

EMAIL LIST
1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6

HIRE ME FOR CONSULTING:
Consulting: https://bit.ly/3dmUl2H

Created with Biorender

Blood Pressure and Heart Disease: https://youtu.be/34cMamNp2Uo?si=uvV2yw0hcrLUDQZG

0:00 - Introduction
1:00 - Why Doctors were Wrong
1:49 - The First Wave of Evidence
3:55 - The Second Wave of Evidence
5:42 - HDL and Mortality, HDL Dysfunction
8:54 - How I'd Approach this

References
*Funding/Conflicts of Interest did not fit in the Description (there is a character limit); however, you can access both by joining my free email list or free Physionic Community

[1] Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707-714. doi:10.1016/0002-9343(77)90874-9

[Study 562] AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267. doi:10.1056/NEJMoa1107579

[Study 563] HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-212. doi:10.1056/NEJMoa1300955

[Study 564] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-2122. doi:10.1056/NEJMoa0706628

[Study 565] Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089-2099.

[Study 566] Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580. doi:10.1016/S0140-6736(12)60312-2

[Study 567] Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539-550. doi:10.1093/eurheartj/eht57

[Study 568] von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J. 2023;44(16):1394-1407. doi:10.1093/eurheartj/ehac605

CRITIQUES, RULES, AND NOTES

Be aware of the following rules before posting comments:
- Please do not post summaries of the video in the comments - it damages retention on the video and YouTube is less likely to promote it (these videos cost me a lot of money to produce).

Critiques of my work are welcome! Please be aware of the following notes & rules before submitting critique:

Be mindful that this content is not all encompassing on the subject at hand and is self-limited for brevity to reach a wider audience. Also, be aware that I receive hundreds of YouTube comments per day, so the only way your critique can be considered is if you follow the steps outlined below. Finally, YouTube auto-deletes links, so I do not see most comments with links attached.

RULES:
If your comment is rude, you will be banned.
If your comment is not about the studies/topics at hand (i.e. extending to other outcomes not discussed) or offers critique with no scientific basis, it is unlikely to receive a response.

If you can follow these rules, I will try to address your critique and if there is merit, I will add an AMENDMENT to the content in question and pin it so everyone can see it (thank you!).

Please use the following link to submit your critique: https://bit.ly/PhysionicCritique

Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.

#hearthealth #heartdiseaseprevention

Mindsip insights from this episode:

Monitor HDL levels to mitigate death risk

Data reveals a U-shaped curve where both very low and very high HDL cholesterol levels are linked to an increased risk of death, acting as a 'yellow flag' for underlying issues.

Rethink high HDL cholesterol as heart attack risk factor

People with lifelong, genetically high HDL cholesterol levels do not have a lower risk of heart attack, confirming it is not inherently protective.

Reevaluate HDL's role in heart health

Multiple lines of evidence, including clinical trials and genetic studies, now prove that HDL is not the 'good cholesterol' it was once thought to be and does not directly protect the heart.

Prioritize HDL particle quality over cholesterol quantity

The emerging concept of 'HDL dysfunction' suggests the quality and function of the HDL particle itself is more important than the amount of cholesterol it contains.

Avoid drugs to raise HDL cholesterol for heart health

Pharmaceutical drugs designed specifically to raise 'good' HDL cholesterol failed to protect against heart disease, and some even caused increased harm and death.

View HDL cholesterol as a marker of overall health

Your HDL cholesterol number should be viewed as a marker of overall health rather than something to directly target with interventions.

DOWNLOAD THE APP

Unlock the wisdom of longevity

DOWNLOAD THE APP

Unlock the wisdom of longevity

DOWNLOAD THE APP

Unlock the wisdom of longevity

Unlock the wisdom of longevity

© Mindsip 2025 – Made with ❤ in Vilnius

Unlock the wisdom of longevity

© Mindsip 2025 – Made with ❤ in Vilnius